Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.

Disc Medicine, Inc. Common Stock

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

OrbiMed

Access Biotechnology

Bain Capital Life Sciences

Novo Holdings

Janus Henderson Investors

Rock Springs Capital

5AM Ventures

Arix Bioscience

Atlas Venture

Nantahala Capital Management

Disc Medicine

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-40.84M -	-35.97M 11.92%	-46.83M 30.19%	-76.43M 63.22%
depreciation and amortization	322K -	32K 90.06%	89K 178.13%	100K 12.36%
deferred income tax	8K -	5.05M 63,025%
stock based compensation	983K -	507K 48.42%	2.09M 312.03%	5.53M 164.72%
change in working capital	337K -	1.29M 281.60%	2.13M 65.24%	-2.95M 238.96%
accounts receivables
inventory
accounts payables	-2.41M -	1.31M 154.61%	526K 60%	-3.74M 811.22%
other working capital	2.75M -	-29K 101.06%	1.60M 5,613.79%	788K 50.72%
other non cash items	6.48M -	1.56M 75.92%	272K 82.56%	290K 6.62%
net cash provided by operating activities	-32.71M -	-27.53M 15.82%	-42.25M 53.45%	-73.46M 73.87%
investments in property plant and equipment	-22K -	-68K 209.09%	-151K 122.06%	-89K 41.06%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-22K -	-68K 209.09%	-151K 122.06%	-89K 41.06%
debt repayment	-14M -	-4.58M 67.26%
common stock issued	20.25M -	89.93M 344.16%	53.50M 40.51%	199.08M 272.11%
common stock repurchased
dividends paid
other financing activites	28M -	4.58M 83.63%	95.48M 1,983.31%	40.30M 57.79%
net cash used provided by financing activities	34.25M -	89.93M 162.59%	148.98M 65.66%	239.38M 60.68%
effect of forex changes on cash
net change in cash	1.52M -	62.33M 4,008.57%	106.58M 70.99%	165.83M 55.60%
cash at beginning of period	3.31M -	25.89M 682.29%	88.21M 240.77%	194.79M 120.82%
cash at end of period	4.83M -	88.21M 1,727.87%	194.79M 120.82%	360.62M 85.13%
operating cash flow	-32.71M -	-27.53M 15.82%	-42.25M 53.45%	-73.46M 73.87%
capital expenditure	-22K -	-68K 209.09%	-151K 122.06%	-89K 41.06%
free cash flow	-32.73M -	-27.60M 15.67%	-42.40M 53.62%	-73.55M 73.46%

COM:DISCMEDICINE

Disc Medicine, Inc.

Last Close

63.51

22/11 17:59

Market Cap

1.92B

Beta: -

Volume Today

70.80K

Avg: -

Preview